Skip to main content

Language: English / GĂ idhlig


Chamber and committees

Question reference: S6W-11099

  • Asked by: Katy Clark, MSP for West Scotland, Scottish Labour
  • Date lodged: 22 September 2022
  • Current status: Answered by Humza Yousaf on 5 October 2022


To ask the Scottish Government whether Fampridine will be made available on the NHS for people living with multiple sclerosis.  


Fampridine (Fampyra ®) was accepted by the Scottish Medicines Consortium (SMC) as a treatment for improvement of walking in adult patients with multiple sclerosis (MS) with walking disability, with a score of 4-7 on the expanded disability status scale (EDSS) in April 2020.

There is also an alternative route of access to fampridine out with the SMC advice through the Peer Approved Clinical System (PACS) Tier Two process, where a doctor considers there would be a clinical benefit for an individual on a case-by-case basis. Individuals can discuss this option with their treating clinician.

It is worth noting that the decision to prescribe any medicine for an individual, and which medicine to prescribe, is entirely one for the clinician in charge of the individual’s care to make, having taken into account their clinical condition.